The
Contrast Media Injectors Global Market Report 2024 by The Business Research
Company provides market overview across 60+ geographies in the seven regions -
Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the
Middle East, and Africa, encompassing 27 major global industries. The report
presents a comprehensive analysis over a ten-year historic period (2010-2021)
and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Contrast Media Injectors Market:
https://www.thebusinessresearchcompany.com/report/contrast-media-injectors-global-market-report
According to The Business Research Company’s Contrast Media Injectors Global
Market Report 2024, The contrast media injectors market size has grown strongly
in recent years. It will grow from $1.6 billion in 2023 to $1.72 billion in
2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be
attributed to increased incidence of chronic diseases, increased diagnostic
imaging procedures, demand for minimally invasive procedures, expansion of
healthcare infrastructure, growing aging population.
The contrast media injectors market size is expected to see strong growth in
the next few years. It will grow to $2.32 billion in 2028 at a compound annual
growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed
to rise in interventional radiology procedures, increasing prevalence of
cancer, focus on patient safety and comfort, globalization of healthcare
services, regulatory support and compliance. Major trends in the forecast
period include automation and connectivity, emergence of dual-head injectors,
advancements in injector technology, focus on patient safety, rise in
interventional radiology procedures, enhanced imaging techniques and
modalities.
Increasing cancer and cardiovascular disease (CVD) are expected to propel the
growth of the contrast media injectors market going forward. Cancer is a
condition that occurs when body cells grow out of control and spread to other
body regions. Cardiovascular disease refers to a type of disease that affects
the heart or blood vessels. Contrast media injectors are applied while
diagnostic imaging to enhance image quality and patient safety and improve
blood flow and tissue perfusion. For instance, in January 2023, according to
the American Cancer Society, a US-based nonprofit cancer advocacy organization,
the number of cancer cases increased from 1,898,160 in 2021 to 1,958,310 in
2023, reflecting a growth of 3.16%. ,
Furthermore, in April 2023, according to the World Heart Federation, a
Switzerland-based non-governmental organization, over 500 million individuals
worldwide will remain impacted by cardiovascular diseases. These conditions led
to 20.5 million fatalities in 2021, representing nearly one-third of the total
global mortality and reflecting a notable rise from the previously estimated
121 million deaths attributed to cardiovascular diseases. Therefore, increasing cancer and
cardiovascular disease (CVD) are driving the growth of the contrast media
injectors market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10187&type=smp
The contrast media injectors market covered in this report is segmented –
1) By Product: Consumables, Injector Systems, Accessories
2) By Type of Injectors: Single Head Injectors, Dual-Head Injectors, Syringe
less Injectors
3) By Application: Radiology, Interventional Cardiology, Interventional
Radiology
4) By End-user: Hospitals, Diagnostics Centers, Ambulatory Surgery Centers
Strategic partnerships are a key trend gaining popularity in contrast media
injectors market. Major companies operating in the contrast media injectors
market are forming partnerships to develop a new type of relationship in which
two or more organizations have similar product developments. For instance, in
December 2022, Qaelum NV, a Belgium-based advanced dose and contrast management
software solutions company, partnered with Ulrich GmbH & Company KG., a
France-based manufacturer and distributor of surgical instruments. With this
partnership, the companies aim to combine their advanced contrast management
solution with the contrast media injectors of Ulrich Medical to support the
needs of hospitals and imaging networks. Furthermore, in December 2021, Bracco
Group, an Italy-based healthcare company, announced a partnership with Guerbet,
a France-based manufacturer of contrast agents. This partnership aim is to
develop Gadopiclenol, a next-generation magnetic resonance imaging (MRI)
contrast agent and to strengthen expertise and investigate untapped areas of
research in pursuit of an agent that would enable early identification and provide
significant health advantages.
The contrast media injectors market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment